Hemostatic Dysfunction Associated with Endocrine Disorders as a Major Risk Factor and Cause of Human Morbidity and Mortality: A Comprehensive Meta-review

Ashraf Mina; Emmanuel J. Favaloro; Jerry Koutts

doi:10.1055/s-2007-1000372

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2007; 33(8): 798-809
DOI: 10.1055/s-2007-1000372

Hemostatic Dysfunction Associated with Endocrine Disorders as a Major Risk Factor and Cause of Human Morbidity and Mortality: A Comprehensive Meta-review

Ashraf Mina¹ ^, ² , Emmanuel J. Favaloro¹ , Jerry Koutts¹

¹Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia
²Australian Institute of Medical Scientists for New South Wales, Sydney, Australia

Abstract

ABSTRACT

We review the association between disorders of endocrine function and hemostasis. The content of more than 570 review articles were appraised to provide the core of 81 key articles referenced in this chapter. The search method used MEDLINE and EMBASE electronic databases and the key words endocrine dysfunction, diabetes, Graves' disease, hypothyroidism, hyperthyroidism, thyrotoxicosis, von Willebrand disease, von Willebrand factor, bleeding disorders, platelets dysfunction, hemostasis dysfunction, and review. Abnormalities of hemostasis, platelets, and endothelium and the presence of microparticles, abnormal expression of adhesion molecules, and elevated von Willebrand factor are all associated with cardiovascular disease and are also features of various endocrine disorders, including diabetes and its complications, insulin resistance, polycystic ovary syndrome, and various thyroid disorders. Related causes and associated factors, including obesity, alcohol, hyperlipidemia, omega fatty acids, vitamin D, serotonin, insulin-like growth factors, angiotensin-converting enzyme, and C-reactive protein, are also discussed in this review.

KEYWORDS

Adhesion molecules - endocrine disorders - endothelium - hemostasis - platelets

Volltext

Referenzen

REFERENCES

1 Tomoriova E, Tkac I, Takac M. Hypercoagulation states. Vnitr Lek. 1993; 39 1114-1119
2 Schafer A I. The hypercoagulable states. Ann Intern Med. 1985; 102 814-828
3 Palumbo P J. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1998; 12 110-119
4 Sowers J R. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 1998; 158 617-621
5 Clemetson K J. Platelet receptors and their role in diseases. Clin Chem Lab Med. 2003; 41 253-260
6 Packham M A, Mustard J F. The role of platelets in the development and complications of atherosclerosis. Semin Hematol. 1986; 23 8-26
7 Nordt T K, Bode C. Endothelium and endogenous fibrinolysis. Z Kardiol. 2000; 89 219-226
8 Becker B F, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol. 2000; 89 160-167
9 Sumpio B E, Riley J T, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol. 2002; 34 1508-1512
10 Nabel E G. Biology of the impaired endothelium. Am J Cardiol. 1991; 68 6C-8C
11 Berkenboom G. Vascular endothelium: target organ of cardiovascular pathologies. Ann Cardiol Angeiol (Paris). 1999; 48 643-646
12 Mancini M, Rubba P. Ischemic cardiopathy: risk factors and their biological role. Ital Heart J. 2000; 1(Suppl 2) 17-22
13 Simon B C, Noll B, Maisch B. Endothelial dysfunction-assessment of current status and approaches to therapy. Herz. 1999; 24 62-71
14 Willerson J T. Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products. Tex Heart Inst J. 1995; 22 13-19
15 Vallance P, Calver A, Collier J. The vascular endothelium in diabetes and hypertension. J Hypertens Suppl. 1992; 10 S25-S29
16 Mehta J L, Nicolini F A, Donnelly W H, Nichols W W. Platelet-leukocyte-endothelial interactions in coronary artery disease. Am J Cardiol. 1992; 69 8B-13B
17 Harrison D G, Kurz M A, Quillen J E, Sellke F W, Mugge A. Normal and pathophysiologic considerations of endothelial regulation of vascular tone and their relevance to nitrate therapy. Am J Cardiol. 1992; 70 11B-17B
18 Pomilio M, Mohn A, Verrotti A, Chiarelli F. Endothelial dysfunction in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002; 15 343-361
19 Horstman L L, Jy W, Jimenez J J, Ahn Y S. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci. 2004; 9 1118-1135
20 Krieglstein C F, Granger D N. Adhesion molecules and their role in vascular disease. Am J Hypertens. 2001; 14 44S-54S
21 Blann A D. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost. 2006; 95 49-55
22 Blann A D, McCollum C N. von Willebrand factor, endothelial cell damage and atherosclerosis. Eur J Vasc Surg. 1994; 8 10-15
23 Blann A. Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci. 1993; 50 125-134
24 Lip G Y, von Blann A. Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res. 1997; 34 255-265
25 van Mourik J A, Romani de Wit T. Von Willebrand factor propeptide in vascular disorders. Thromb Haemost. 2001; 86 164-171
26 Nitu-Whalley I C, Lee C A. Acquired von Willebrand syndrome-report of 10 cases and review of the literature. Haemophilia. 1999; 5 318-326
27 Rinder M R, Richard R E, Rinder H M. Acquired von Willebrand's disease: a concise review. Am J Hematol. 1997; 54 139-145
28 Jakway J L. Acquired von Willebrand's disease. Hematol Oncol Clin North Am. 1992; 6 1409-1419
29 Delonca J, Balteaux V, Giraud T, Sanchez R Y. EDRF/NO and endothelial functions. Arch Mal Coeur Vaiss. 1993; 86 1617-1624
30 Hunley T E, Iwasaki S, Homma T, Kon V. Nitric oxide and endothelin in pathophysiological settings. Pediatr Nephrol. 1995; 9 235-244
31 Vapaatalo H, Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit. 2001; 7 1075-1085
32 Naseem K M. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med. 2005; 26 33-65
33 Rush J W, Denniss S G, Graham D A. Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can J Appl Physiol. 2005; 30 442-474
34 Banfi C, Mussoni L, Tremoli E. PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms. Minerva Endocrinol. 2002; 27 181-191
35 De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest. 2002; 25 899-904
36 Malenfant M. Diabetic retinopathy: pathogenesis, risk factors, clinical picture, classification. Bull Soc Belge Ophtalmol. 1995; 256 11-23
37 Hano T, Nishio I. Hypertension in the patients with impaired glucose tolerance. Nippon Rinsho. 1996; 54 2687-2691
38 Schneider D J, Nordt T K, Sobel B E. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes. 1993; 42 1-7
39 Kohler H P. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly. 2002; 132 241-252
40 Wirth A, Rothenfelde B. Metabolic syndrome. Versicherungsmedizin. 1996; 48 193-199
41 Dunn E J, Grant P J. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med. 2005; 5 323-332
42 Banga J D. Coagulation and fibrinolysis in diabetes. Semin Vasc Med. 2002; 2 75-86
43 Frohlich J, Steiner G. Dyslipidaemia and coagulation defects of insulin resistance. Int J Clin Pract Suppl. 2000; 113 14-22
44 Ghosh K. Thrombohaemorrhagic balance in diabetes mellitus. J Indian Med Assoc. 2002; 100 428-433
45 Ferrannini E, Galvan A Q, Gastaldelli A et al.. Insulin: new roles for an ancient hormone. Eur J Clin Invest. 1999; 29 842-852
46 Juhan-Vague I, Alessi M C, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med. 1996; 28 371-380
47 Janka H U. Insulin resistance and cardiovascular complications. Wien Klin Wochenschr. 1994; 106 758-762
48 Blann A D, Lip G Y. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabet Med. 1998; 15 634-642
49 Porta M, Molinatti P, La Selva M, Molinatti G M. Endothelium and its morphofunctional changes in the pathogenesis of diabetic microangiopathy. Minerva Med. 1988; 79 915-929
50 McMillan D E. The effect of diabetes on blood flow properties. Diabetes. 1983; 32(Suppl 2) 56-63
51 Carr M E. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001; 15 44-54
52 McDonagh P F, Hokama J Y. Microvascular perfusion and transport in the diabetic heart. Microcirculation. 2000; 7 163-181
53 Sobol A B, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract. 2000; 50 1-16
54 Varughese G I, Tomson J, Lip G Y. Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract. 2005; 59 798-816
55 Luscher T F, Oemar B S, Yang Z, Noll G. Molecular and cellular mechanisms of arteriosclerosis and restenosis: possibilities of gene therapy. Z Kardiol. 1996; 85 495-508
56 Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res. 2005; 2 16-23
57 Arjomand H, Roukoz B, Surabhi S K, Cohen M. Platelets and antiplatelet therapy in patients with diabetes mellitus. J Invasive Cardiol. 2003; 15 264-269
58 Colwell J A, Nesto R W. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003; 26 2181-2188
59 Kirpichnikov D, Sowers J R. Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab. 2001; 12 225-230
60 Savage P J. Treatment of diabetes mellitus to reduce its chronic cardiovascular complications. Curr Opin Cardiol. 1998; 13 131-138
61 McMillan D E. Deterioration of the microcirculation in diabetes. Diabetes. 1975; 24 944-957
62 Kessler L, Wiesel M L, Attali P, Mossard J M, Cazenave J P, Pinget M. Von Willebrand factor in diabetic angiopathy. Diabetes Metab. 1998; 24 327-336
63 Porta M, La Selva M, Molinatti P A. von Willebrand factor and endothelial abnormalities in diabetic microangiopathy. Diabetes Care. 1991; 14 167-172
64 Bell D S. Alcohol and the NIDDM patient. Diabetes Care. 1996; 19 509-513
65 Lyons D. Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease. Int J Cardiol. 1997; 62(Suppl 2) S101-S109
66 Simopoulos A P. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr. 1991; 54 438-463
67 Gerster H. Prevention of platelet dysfunction by vitamin E in diabetic atherosclerosis. Z Ernahrungswiss. 1993; 32 243-261
68 Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl. 1999; 71 S22-S24
69 Lobo R A, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000; 132 989-993
70 Zdrojewicz Z, Sztuka-Pietkiewicz A, Zarzycki A, Karwacki J. Serotonin-structure, activity and clinical significance. Postepy Hig Med Dosw. 1998; 52 637-654
71 McCarty M F. Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke - just say NO to stroke!. Med Hypotheses. 2000; 55 386-403
72 Ferns G A, Motani A S, Anggard E E. The insulin-like growth factors: their putative role in atherogenesis. Artery. 1991; 18 197-225
73 Tschudi M R, Noll G, Luscher T P. Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors. Schweiz Med Wochenschr. 1997; 127 636-649
74 Mombouli J V. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Drugs. 1997; 54(Suppl 5) 12-22
75 Koppel H, Eber B, Gasser R, Klein W. Recent molecular and pharmacologic aspects of ACE inhibitors. Wien Med Wochenschr. 1995; 145 633-637
76 Ridker P M. Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease. Haemostasis. 1997; 27(Suppl 1) 2-11
77 Klein M, Barbe F, Kaminsky P, Duc M. Disorders of hemostasis in dysthyroidism. Pathol Biol (Paris). 1993; 41 268-275
78 Ford H C, Carter J M. Haemostasis in hypothyroidism. Postgrad Med J. 1990; 66 280-284
79 Squizzato A, Romualdi E, Buller H R, Gerdes V E. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab. 2007; 92 2415-2420
80 Squizzato A, Gerdes V E, Ageno W, Buller H R. The coagulation system in endocrine disorders: A narrative review. Intern Emerg Med. 2007; 2 76-83
81 Michiels J J, Schroyens W, Berneman Z, van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost. 2001; 7 113-115

Ashraf Mina

Institute of Clinical Pathology and Medical Research (ICPMR)

Westmead Hospital, Westmead, N.S.W. 2145, Australia

eMail: ashraf.mina@swahs.health.nsw.gov.au